We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Implementation of Guidelines on Hereditary or Familial Colorectal Cancer (RISCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00929097
Recruitment Status : Unknown
Verified June 2009 by Radboud University.
Recruitment status was:  Enrolling by invitation
First Posted : June 26, 2009
Last Update Posted : June 26, 2009
Information provided by:

Study Description
Brief Summary:
The aim of this study is to improve clinicians' calculation, interpretation and communication of familial colorectal cancer risk, as well as patients' risk perception and uptake of referral for genetic counselling or for surveillance by colonoscopy for their relatives at risk.

Condition or disease Intervention/treatment
Colorectal Neoplasms, Hereditary Nonpolyposis Other: Implementation aids Other: Control

Detailed Description:

Regular colonoscopy is effective in reducing morbidity and mortality due to colorectal cancer (CRC) in patients at increased familial CRC risk. Currently, the majority of these at-risk individuals are not properly referred for increased surveillance by colonoscopy or genetic counselling. In 2008, a national multidisciplinary evidence-based guideline on familial and hereditary CRC was launched in the Netherlands. Clinicians have new tasks in familial CRC risk calculation, interpretation and communication. A clustered randomized controlled trial including an effect, process and cost evaluation will be conducted in eighteen Dutch hospitals to determine the most cost effective way to implement these new guidelines.

Surgeons and gastroenterologists in both the intervention group and the control group will receive background information on familial colorectal cancer risk and the guidelines. Patients and clinicians in the intervention group will receive an additional intervention strategy.

The effect evaluation is done by assessing the number of CRC patients for whom correct risk calculation, interpretation and communication is performed, as well as patients' uptake of the recommended follow up policy. The actual exposure to the different elements of the implementation procedure and the experiences of users will be assessed in the process evaluation. The costs of the implementation procedure will be determined by means of a cost evaluation.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Implementation of Guidelines on Hereditary or Familial Colorectal Cancer Risk Calculation and Risk Communication
Study Start Date : October 2009
Estimated Primary Completion Date : July 2011
Estimated Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Implementation aids Other: Implementation aids
  • Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids
  • Clinicians receive the guidelines and a risk communication tool, as well as education
Active Comparator: Control Other: Control
Dissemination of guidelines

Outcome Measures

Primary Outcome Measures :
  1. The number of colorectal cancer patients following the most optimal follow up program according to the guidelines. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. The number of patients for whom MSI testing was performed based on the MIPA criteria [ Time Frame: 1 year ]
  2. The number of CRC patients for whom a correct familial CRC risk is calculated by clinicians (as compared to formally calculated risks) [ Time Frame: 1 year ]
  3. The number of CRC patients for whom a calculated familial CRC risk is correctly interpreted by clinicians [ Time Frame: 1 year ]
  4. The number of CRC patients with whom a calculated familial CRC risk and/or follow up policy is communicated by clinicians [ Time Frame: 1 year ]
  5. Patients' uptake of the follow up policy [ Time Frame: 1 year ]
  6. Actual exposure to the different elements of the implementation strategy [ Time Frame: 1 year ]
  7. Experiences of clinicians and patients with the different elements of the implementation strategy [ Time Frame: 1 year ]
  8. Costs of the implementation procedure [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of colorectal cancer before the age of 70
  • Diagnosed in one of the participating hospitals
  • Able to read and understand Dutch

Exclusion Criteria:

  • Previous referral for genetic counseling
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00929097

Sponsors and Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
Cardiff University
Erasmus Medical Center
Leiden University Medical Center
University Medical Center Groningen
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Comprehensive Cancer Centres
Principal Investigator: Nicoline Hoogerbrugge, MD, PhD Radboud University
Principal Investigator: Rosella PMG Hermens, PhD Radboud University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: E.A.R.J. Lohman, Chairman Hospital Board, Radboud University Nijmegen Medical Centre
ClinicalTrials.gov Identifier: NCT00929097     History of Changes
Other Study ID Numbers: ZonMw 80-82315-98-09005
First Posted: June 26, 2009    Key Record Dates
Last Update Posted: June 26, 2009
Last Verified: June 2009

Keywords provided by Radboud University:
Colorectal Neoplasms, (Hereditary Nonpolyposis)
Health Plan Implementation
Decision Support Techniques
Risk assessment
Familial colorectal cancer risk
Risk assessment tool

Additional relevant MeSH terms:
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases